The U.S. Centers for Disease Control and Prevention (CDC) confirmed a second U.S. case of the new coronavirus from China in a Chicago woman, and said as many as 63 potential cases were being investigated as the sometimes deadly illness continues to spread around the globe.
Doctors studying lung tissue from people with vaping-related injuries have ruled out one diagnosis as a probable explanation of how vaping harms the lungs, further deepening the mystery over the exact cause of hundreds of illnesses in the United States.
Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens
Antibiotics, Clinical Trials, EMA, European Medicines Agency, FDA, Gram-negative pathogens, Marketing Authorization Application (MAA), New Drug Applications, Nosocomial Pneumonia, R&DShionogi & Co. Ltd. announced results from APEKS-NP, an international, double-blind, randomized Phase III clinical trial evaluating the efficacy and safety of the investigational antibiotic cefiderocol in patients with nosocomial pneumonia (NP).
FDA Approves Expanded Use For Merck’s Zerbaxa For Treatment Of Adults With HABP/VABP
Antibacterials, Approvals, Biopharmaceutical, Clinical Data, Drug-resistant bacteria, FDA, FDA/Regulatory, Gram-negative microorganisms, Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia (HABP/VABP), Supplemental New Drug Application (sNDA)The U.S. FDA approved Merck’s supplemental New Drug Application for the use of Zerbaxa for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.
GSK Cuts Flu and Pneumonia Vaccines After Disappointing Data
Analysts, Business, Clinical Data, Endometrial Cancer, Fast Track Designation, FDA, Immunotherapies, Influenza, Multiple myeloma, Oncology, Ovarian Cancer, PARP Inhibitors, Pneumonia, Product Pipeline, Quarterly results, R&D, Respiratory Syncytial Virus, VaccinesIn GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.
A team from Uganda’s Makerere University is the only African winner in the 2014-2015 Big Ideas Contest for its app that could aid in early detection of pneumonia. The app, […]
